Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DK210 + chemotherapy
- Development stage
- Unknown
- Lead developer
- DEKA Biosciences
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous (for DK210), Intravenous (for Chemotherapy Agents; Specific Route May Depend On The Chosen Chemotherapy)
01
Overview
DK210 + chemotherapy refers to a combination regimen of DK210, a next-generation tumor-targeted dual immunocytokine, with standard chemotherapy agents. DK210 (also referred to as DK210 (EGFR)) consists of wild-type interleukin-2 (IL-2) coupled to an Epstein Barr Virus (EBV) IL-10 variant, both fused onto a single-chain fragment variable (scFv) that targets the epidermal growth factor receptor (EGFR). The molecule is designed to deliver immune-activating cytokines specifically to EGFR-overexpressing tumor cells, enhancing immune activation (notably effector T cell and NK cell expansion) while reducing regulatory T cell (Treg) expansion and limiting cytokine release syndrome (CRS)-related toxicity. The chemotherapy component refers to the addition of standard-of-care cytotoxic drugs, although the precise agents are not universally specified and may vary by tumor type or protocol. This combination is being explored for various advanced solid tumors characterized by EGFR overexpression, with the aim of enhancing anti-tumor efficacy and improving safety over existing immunotherapy and chemotherapy regimens[1][2][3][5][6].
- Other names
- DK210 (EGFR) + chemotherapy
02
Targets
EGFR (Epidermal growth factor receptor)IL10RA (Interleukin-10 Receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)DNA
Beyond the preview
Go deeper on DK210 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DK210 + chemotherapy.